Early breast cancer often requires 4-6 cycles of chemotherapy. The main chemotherapeutic agents used in the early stage of breast cancer are adriamycin, cyclophosphamide and paclitaxel. Adriamycin mainly includes Adriamycin, Epirubicin and Pyridoxine, while paclitaxel includes Paclitaxel and Docetaxel. For early chemotherapy of breast cancer, the decision to use two or three of these three chemotherapeutic agents for chemotherapy needs to be based on the patient’s specific situation and the high risk factors for postoperative recurrence. If two chemotherapeutic drugs are chosen, 4-6 cycles of chemotherapy are often sufficient. If all three chemotherapeutic agents are required, these two chemotherapeutic agents need to be administered separately because of the cardiotoxicity of adriamycin and paclitaxel, when 8 cycles of chemotherapy are required, often followed by 4 cycles of adriamycin combined with cyclophosphamide followed by 4 cycles of paclitaxel as a single agent chemotherapy.